The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease.

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

The investment is being led by Bain Capital’s Private Equity teams in Asia and North America together with ... to Bain Capital. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), ...

Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking boom in Japan. The deal values Mitsubishi Tanabe Pharma at about ¥510 ...

today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (“Tanabe Pharma”, “MTPC” or “the Company”) in a carve-out transaction from ...

Mitsubishi UFJ Morgan Stanley Securities and BofA Securities are serving as financial advisors, and Morrison Foerster, Mori, Hamada & Matsumoto and Ropes & Gray are serving as legal advisors to Bain ...

MTPC employs over 5,000 people globally. As an independent company, Tanabe Pharma will continue to build on its legacy of medical innovation while developing new opportunities for growth through ...